Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib) ; volume:22 ; number:1 ; day:23 ; month:8 ; year:2024 ; pages:1-21 ; date:12.2024
Cell communication and signaling ; 22, Heft 1 (23.8.2024), 1-21, 12.2024
- Creator
-
Kot, Magdalena
Simiczyjew, Aleksandra
Wądzyńska, Justyna
Ziętek, Marcin
Matkowski, Rafał
Nowak, Dorota
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12964-024-01788-3
- URN
-
urn:nbn:de:101:1-2411120854116.075311048432
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kot, Magdalena
- Simiczyjew, Aleksandra
- Wądzyńska, Justyna
- Ziętek, Marcin
- Matkowski, Rafał
- Nowak, Dorota
- SpringerLink (Online service)
Other Objects (12)
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines